- Home
- OCFT vs TVRD Comparison
OCFT vs TVRD Comparison
Compare OCFT & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFT
- TVRD
- Stock Information
- Founded
- OCFT 2015
- TVRD 2017
- Country
- OCFT China
- TVRD United States
- Employees
- OCFT N/A
- TVRD N/A
- Industry
- OCFT Computer Software: Programming Data Processing
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- OCFT Technology
- TVRD Health Care
- Exchange
- OCFT Nasdaq
- TVRD Nasdaq
- Market Cap
- OCFT 236.7M
- TVRD 246.5M
- IPO Year
- OCFT 2019
- TVRD N/A
- Fundamental
- Price
- OCFT $7.19
- TVRD $25.77
- Analyst Decision
- OCFT
- TVRD Strong Buy
- Analyst Count
- OCFT 0
- TVRD 3
- Target Price
- OCFT N/A
- TVRD $60.67
- AVG Volume (30 Days)
- OCFT 52.1K
- TVRD 56.7K
- Earning Date
- OCFT 08-15-2025
- TVRD 05-13-2025
- Dividend Yield
- OCFT N/A
- TVRD N/A
- EPS Growth
- OCFT N/A
- TVRD N/A
- EPS
- OCFT N/A
- TVRD N/A
- Revenue
- OCFT $260,815,958.00
- TVRD N/A
- Revenue This Year
- OCFT N/A
- TVRD N/A
- Revenue Next Year
- OCFT $6.37
- TVRD N/A
- P/E Ratio
- OCFT N/A
- TVRD N/A
- Revenue Growth
- OCFT N/A
- TVRD N/A
- 52 Week Low
- OCFT $0.87
- TVRD $8.13
- 52 Week High
- OCFT $7.38
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- OCFT 61.60
- TVRD N/A
- Support Level
- OCFT $6.96
- TVRD N/A
- Resistance Level
- OCFT $7.20
- TVRD N/A
- Average True Range (ATR)
- OCFT 0.16
- TVRD 0.00
- MACD
- OCFT -0.04
- TVRD 0.00
- Stochastic Oscillator
- OCFT 74.41
- TVRD 0.00
About OCFT OneConnect Financial Technology Co. Ltd.
OneConnect Financial Technology Co Ltd is a technology-as-a-service provider for the financial services industry. It integrates extensive expertise in the industry with market technology to provide technology applications and technology-enabled business services to financial institutions. The integrated solutions and platforms it provides include digital banking solutions, digital insurance solutions, and the Gamma Platform, a technology infrastructure platform for financial institutions. Geographically, the company generates substantially all of its revenue from its business in the People's Republic of China (PRC).
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.